When was Genomadix founded?

Genomadix was founded in 2021 and raised its 1st funding round 1 year after it was founded.

Where is Genomadix located?

Genomadix is headquartered in Ottawa, Canada.

How many employees does Genomadix have?

As of Sep 30, 2026, the latest employee count at Genomadix is 40.

Is Genomadix a funded company?

Genomadix is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jul 19, 2022.

When was the latest funding round of Genomadix?

Genomadix's latest funding was a $***** Seed round on Aug 30, 2022, with participation from 1 investor.

Where does Genomadix rank among its competitors?

Genomadix ranks 17th amongst 78 active competitors, of which 18 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sensible Biotechnologies, which secured $47M in Oct, 2026.

Who are the top competitors of Genomadix?

Genomadix's top competitors include Twist Bioscience, Ansa Biotechnologies and NTxBio. Among them, Sensible Biotechnologies secured the most recent funding round in October, 2026.

Genomadix - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of a portable molecular analyzer for diagnostic purposes. The company has developed a "Genomadix Cube" that uses the gold standard of Polymerase Chain Reaction (PCR) to detect the increased fluorescence and automatically generate a test result. It is used for the detection of COVID-19 and bacterial strains.

Website: genomadix.com
Phone Number: +1 **********

Key Metrics

Founded Year

2021

Location

Ottawa, Canada

Stage

Seed

Latest Funding Round

Seed, Aug 30, 2022, $*****

Investors

Mayo Clinic & 1 more

Ranked

17^th among 78 active competitors

Employee Count

40 as on Sep 30, 2026

Similar Companies

Twist Bioscience & 84 more

View Genomadix's full profile

Genomadix has raised funding over 2 rounds. Its first funding round was on Jul 19, 2022. Its latest funding round was a Seed round on Aug 30, 2022 for $*****. 1 investor participated in its latest round. Genomadix has 2 institutional investors.

Here is the list of recent funding rounds of Genomadix:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 30, 2022	1989053	Seed	4904775	3080653	3568857	6509637
Jul 19, 2022	2842089	Seed	4852942	4012899	3801183	ICW Healthcare Ventures

Access funding benchmarks and valuations. Sign up today!

View details of Genomadix's funding rounds and investors

The founders of Genomadix is Paul Lem. Steve Edgett is the CEO of Genomadix.

Here are the details of Genomadix's key team members:

Paul Lem: Chief Medical Officer & Founder of Genomadix.
Steve Edgett: CEO of Genomadix.

View details of Genomadix's Founder profiles and Board Members

Genomadix's employee count trend

Genomadix has 40 employees as of Sep 26. Here is Genomadix's employee count trend over the years:

Uncover Genomadix's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Genomadix include Twist Bioscience, Ansa Biotechnologies and NTxBio. Here is the list of Top 10 competitors of Genomadix, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Twist Bioscience 2013, San Francisco (United States), Public	Developer of a semiconductor-based DNA synthesis platform	$321M	Foresite Capital, Fidelity Investments & 39 others	74/100
2nd	Ansa Biotechnologies 2017, Berkeley (United States), Series B	Provider of DNA synthesis technology using enzymes	$177M	Northpond Ventures, Fifty Years & 17 others	66/100
3rd	NTxBio 2016, Santa Fe (United States), Series B	Developer of automated cell free systems for RNA protein production	$85.1M	RA Capital Management, Anzu Partners & 5 others	61/100
4th	Stilla Technologies 2013, Villejuif (France), Acquired	Developer of digital PCR solution for research	$53.1M	Illumina Ventures, LBO France & 11 others	61/100
5th	Biocartis 2007, Mechelen (Belgium), Public	Manufacturer of automated molecular diagnostic systems for oncology biomarker testing	$305M	Johnson & Johnson Innovation – JJDC, Advent Life Sciences ... & 18 others	58/100
6th	Camena Bioscience 2016, Cambridge (United Kingdom), Series A	Developer of a nucleic acid synthesis technology platform	$10M	Mercia, Mercia Ventures & 15 others	56/100
7th	DNA Script 2014, Paris (France), Series C	Developer of benchtop DNA printer for nucleic acid synthesis	$315M	T. Rowe Price, Baillie Gifford & 27 others	54/100
8th	GenMark Diagnostics 1993, San Diego (United States), Acquired	Provider of instruments and test panels for multiplexed molecular diagnostics	$8.56M	SLR Investment Corp, VIDANT Capital	54/100
9th	Sensible Biotechnologies 2021, Wilmington (United States), Series A	Developer of mRNA technology for therapeutics and vaccines	$51.3M	Y Combinator, BlueYard & 17 others	50/100
10th	OriCiro Genomics 2018, Tokyo (Japan), Acquired	Developer of technologies for DNA synthesis and amplification	$10.9M	UTEC, Asahi Kasei & 3 others	48/100
17th	Genomadix 2021, Ottawa (Canada), Seed	Developer of a portable molecular analyzer for diagnostic purposes	-	Mayo Clinic, ICW Healthcare Ventures	39/100